Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2010, Article ID 135354, 8 pages
Research Article

Thrombopoietin Receptor Levels in Tumor Cell Lines and Primary Tumors

1Oncology Biology, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426-2990, USA
2Oncology Biomarkers, GlaxoSmithKline, Morphotek, 210 Welsh Pool Road, Exton, PA 19341, USA
3Oncology Clinical, GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA
4Oncology Biomarkers, GlaxoSmithKline, Astellas Pharmaceuticals, 3 Parkway North, Deerfield, IL 60015, USA
5Oncology Clinical, GlaxoSmithKline, Oncology R&D, Building 11, 1-3 Bridge Road, Stockley Park West, Uxbridge, Middlesex UB11 1BT, UK
6Oncology Biomarkers, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426-2990, USA
7Oncology Clinical, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426-2990, USA

Received 3 June 2010; Accepted 24 September 2010

Academic Editor: Edgar Selzer

Copyright © 2010 Connie L. Erickson-Miller et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Thrombopoietin (TPO) receptor agonists represent a new approach for the treatment of thrombocytopenia, which may develop as a consequence of immune thrombocytopenia, chemotherapy treatment, chronic hepatitis C infection, or myelodysplastic syndromes. There are concerns that use of certain growth factors can hasten disease progression in some types of hematologic malignancies and solid tumors. In this study, expression of MPL (TPO-R) mRNA was examined in tumor cell lines, patient tumor samples (renal cell carcinoma, prostatic carcinoma, soft tissue and bony/cartilage sarcoma, colon cancer, and lymphoma), and normal tissues using microarray analysis and qRT-PCR. MPL mRNA is expressed at very low or undetectable levels compared with erythropoietin receptor (EPOR), human epidermal growth factor (ERBB2; HER2), and insulin-like growth factor-1 receptor (IGF1R) in these patient samples. These data suggest TPO-R agonists will likely preferentially stimulate proliferation and differentiation of cells of megakaryocytic lineage, potentially demonstrating their utility for correcting thrombocytopenia in clinical settings.